[Skip to Content]

Upstate Active Clinical Trials

Study Title:

2215-CL-0201: A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Upstate Institutional Review Board (IRB) Number:

890706

Study/Protocol ID:

2215-CL-0201

Study Phase:

2/3

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

Where will the study take place?

Upstate Cancer Center - All Procedures

ClinicalTrials.Gov ID:

NCT02752035

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Alexandra Koulouris, BA
Phone: 315-464-8237
Email: kouloura@upstate.edu

Return to Previous Page || Search Again

Top